SELLAS Life Sciences Group Inc (SLS) gains 8.14% for July 21

Equities Staff  |

SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares gained 8.14%, or $0.7 per share, to close Wednesday at $9.30. After opening the day at $9.00, shares of SELLAS Life fluctuated between $9.55 and $8.80. 404,437 shares traded hands a decrease from their 30 day average of 1,029,440. Wednesday's activity brought SELLAS Life’s market cap to $140,288,212.

SELLAS Life is headquartered in Camden, Delaware, and employs more than 60 people.

About SELLAS Life Sciences Group Inc

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, NPS, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.

Visit SELLAS Life Sciences Group Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on SELLAS Life Sciences Group Inc and to follow the company’s latest updates, you can visit the company’s profile page here: SELLAS Life Sciences Group Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content